Diagnos Inc. Receives Positive Flash Report from Emerging Growth Research on CARA AI Platform Progress and Market Potential
Diagnos Inc., a corporation specializing in early detection of eye-related health issues using Artificial Intelligence (AI) technology, has received a new flash report from Emerging Growth Research. The report highlights the progress made by Diagnos towards key regulatory approvals and the increasing commercialization potential of its CARA (Computer Assisted Retinal Analysis) AI platform. The company is on track to achieve significant regulatory milestones that could expand the market for CARA, a cloud-based AI software platform that detects retinal diseases and systemic conditions using standard fundus cameras.
Emerging Growth Research recognizes Diagnos' strategic positioning to benefit from global trends such as the aging population, rising prevalence of diabetes-related eye diseases, shortage of eye-care specialists, and the growing use of AI in healthcare diagnostics. Management estimates an addressable market opportunity of approximately C$11 billion for CARA, while an independent study forecasts the global AI-powered retinal image analysis market to grow from US$2.65 billion in 2023 to US$9.4 billion by 2033.
Emerging Growth Research is an independent firm that focuses on identifying and analyzing emerging growth companies in various sectors. The firm provides institutional-quality equity research coverage and supports public companies through investor awareness initiatives and participation in the Emerging Growth Conference platform.
Diagnos is a Canadian corporation publicly traded on the TSX Venture Exchange, dedicated to the early detection of critical eye-related health issues. By leveraging AI technology, Diagnos aims to provide healthcare clinicians with more information to improve diagnostic accuracy, streamline workflows, and enhance patient outcomes globally.
For more information about Diagnos, please visit their website. This news release may contain forward-looking information, and Diagnos disclaims any intention or obligation to publicly update or revise such information. The TSX Venture Exchange and its Regulation Services Provider do not accept responsibility for the accuracy of this release.